Modulating biomaterial cell interactions for targeting and regenerative therapeutic applications
Hélder Santos a b
a University Medical Center Groningen, Department of Biomedical Engineering, Groningen, Netherlands
b University of Helsinki
Proceedings of Advanced materials and devices for nanomedicine (AMA4MED)
VALÈNCIA, Spain, 2022 May 3rd - 4th
Organizers: Claudia Tortiglione and María Moros
Invited Speaker, Hélder Santos, presentation 006
DOI: https://doi.org/10.29363/nanoge.amamed.2022.006
Publication date: 22nd April 2022

The recent cutting-edge advances on nanomaterials is anticipated to overcome some of the therapeutic window and clinical applicability of many drug/peptide molecules and can also act as innovative theranostic platforms and tool for the clinic in the future [1-4].

In the last decade, research on cancer and cardiovascular diseases resulted in a new set of potential treatments with promising results in the clinics [5-9]. Amongst the different experimental treatments, active cancer immunotherapy and targeted to the injured heart hold great promise for the future treatment of these diseases. In this work, prominent nanosystems, such as biohybrid nanocomposites made of different nanoparticles (porous silicon and oncolytic virus) and cancer cell-based membrane materials are presented and discussed as potential platforms for the individualization of medical intervention and biomedical applications.

Examples on how these biohybrid nanomaterials can be prepared and scaled-up, as well as how they can be used to enhance the drug’s targetability, intracellular drug delivery for both cancer chemo- and immune-therapy applications as well as other applications, will be highlighted and discussed.

Overall, our results suggest that biohybrid nanomaterials are a versatile and advanced platform for treatment of different diseases with an interesting potential for present and future clinical impact given its easy tailorability to each patient.

[1] Zhang, [..], Santos*, M. Hai*, D. A. Weitz*, Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 7744.

[2] Liu*, [...], Santos*, Adv. Mater. 2018, 30, 1703393.

[3] Ferreira*, [...], Santos*, Adv. Funct. Mater. 2018, 28, 1705134.

[4] Ferreira*, [...], Santos*, Small 2017, 13, 1701276.

[5] Fontana*, [...], Santos*, Adv. Mater. 2017, 29, 1603239.

[6] Fontana, [...], Cerullo*, Santos*, ACS Nano 2019, 13, 6477.

[7] Yong, [...], Santos*, Yang*, Nature Commun. 2019, 10, 3838.

[8] Fusciello, [...], Santos*, Cerullo*, Nature Commun. 2019, 10, 5747.

[9] Zhang, [..] Fang*, Santos*, Zhang*, Sci. Adv. 2022, 8, eabj8207.

© FUNDACIO DE LA COMUNITAT VALENCIANA SCITO
We use our own and third party cookies for analysing and measuring usage of our website to improve our services. If you continue browsing, we consider accepting its use. You can check our Cookies Policy in which you will also find how to configure your web browser for the use of cookies. More info